05/13/2026
This makes you say WOW! And although the method was a little loose, it still shows us there is something there we did not expect…
A new breast cancer study just came out in JAMA Network Open, and one number is going to get a lot of attention.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848788
Women with breast cancer and type 2 diabetes who used GLP-1 drugs had a reported 91% lower relative hazard of death compared with women treated with insulin or metformin.
That is a massive number.
These are the drugs most people know as Ozempic, Wegovy, Mounjaro, and Zepbound.
So the obvious question is: are these drugs somehow protecting women after breast cancer?
Maybe.
But this is where we need to be very careful.
This study does not prove that Ozempic or Mounjaro prevents breast cancer recurrence. It does not prove these drugs directly fight breast cancer. And it does not show that fewer women died specifically from breast cancer.
The endpoint was all-cause mortality, meaning death from any cause. That could include breast cancer, but it could also include heart disease, stroke, infection, or anything else. 
The recurrence endpoint also needs a little caution. Recurrence-free survival in this study was based on medical codes for metastatic or distant recurrence. That is not the same thing as an oncologist reviewing every scan, biopsy, pathology report, and clinical note to confirm each recurrence. 
So no, this is not proof.
But I would not dismiss it either.
The researchers used a large electronic health record database and started with more than 841,000 women with breast cancer. They focused on women with stage I to III breast cancer who also had obesity or type 2 diabetes. Patients with stage IV disease or known metastatic disease were excluded. 
In the diabetes group, the numbers looked striking.
Deaths occurred in 0.8% of GLP-1 users compared with 7.7% of patients treated with insulin or metformin. That is where the 91% relative reduction comes from. 
The recurrence numbers also favored the GLP-1 group. Coded metastatic recurrences occurred in 1.4% of GLP-1 users compared with 3.9% of insulin or metformin users. 
Among women with obesity and breast cancer, GLP-1 users also did better than nonusers. Deaths occurred in 1.2% versus 3.7%, and coded recurrences occurred in 2.6% versus 5.8%. 
Those are interesting numbers.
But here is the part that keeps me from overreacting.
The results looked much less dramatic when GLP-1 drugs were compared with SGLT2 inhibitors, another newer class of diabetes drugs that also has major heart and metabolic benefits.
In that comparison, deaths were almost identical: 7.0% with GLP-1 drugs and 7.1% with SGLT2 inhibitors. Coded recurrences were also very similar: 3.1% versus 3.3%. 
That matters.
If GLP-1 drugs had a strong, unique anticancer effect, you might expect them to clearly outperform another modern diabetes drug class. They really did not, at least in the unadjusted analysis.
That does not mean GLP-1 drugs are irrelevant. It may mean the real story is broader than GLP-1 itself.
Maybe this is about metabolic health.
Maybe it is about weight loss.
Maybe it is about insulin resistance.
Maybe it is about inflammation.
Maybe it is about cardiovascular risk.
Maybe it is about the fact that patients getting newer metabolic drugs are different from patients on older diabetes regimens. They may have better access to care, more physician follow-up, better insurance coverage, or more aggressive risk-factor management.
That is the problem with retrospective database studies. They can show signals. They can generate hypotheses. But they cannot prove causation.
There are also some breast cancer-specific issues. Breast cancer is not one disease. ER status matters. HER2 status matters. Tumor grade, lymph nodes, genomic risk, endocrine therapy adherence, surgery, radiation, chemotherapy, and systemic therapy all matter.
Large electronic health record studies often do not capture those details cleanly. The authors acknowledge that the cancer details were incomplete. They also did not have patient-level weight loss data, so we do not know whether the apparent benefit was related to actual weight loss, better blood sugar, lower insulin levels, improved inflammation, cardiovascular benefit, or something else. 
So where do I land?
I would not call GLP-1 drugs breast cancer drugs.
Not yet.
I would not tell breast cancer survivors to start Ozempic or Mounjaro because of this study.
But I also would not ignore the signal.
The bigger message may be that the body’s metabolic environment matters after breast cancer.
Obesity is not just extra weight. It is often tied to insulin resistance, chronic inflammation, hormonal changes, immune dysfunction, and metabolic stress. Type 2 diabetes brings its own problems: high insulin, high glucose, vascular disease, inflammation, and higher cardiovascular risk.
All of that can influence long-term health. And it may influence cancer outcomes too.
For patients, my takeaway is pretty simple: if you have had breast cancer and also have obesity, prediabetes, insulin resistance, or type 2 diabetes, this is worth discussing with your oncology team, primary care doctor, or endocrinologist.
Not because GLP-1 drugs are proven to prevent recurrence.
They are not.
But because metabolic health should not be treated as an afterthought in breast cancer survivorship.
The tumor matters. The treatment matters. Surgery, radiation, chemotherapy, endocrine therapy, HER2-directed therapy, immunotherapy, CDK4/6 inhibitors, and appropriate surveillance still matter enormously.
But the terrain matters too.
This study does not prove that Ozempic or Mounjaro prevents breast cancer recurrence.
What it does suggest is that the metabolic health conversation in breast cancer survivorship may need to get a lot more serious.
